Amgen (AMGN)

NASDAQ:AMGN

AMGN

Amgen

RESEARCH TOOLSreports

Want to see AMGN full AI Analyst Report?

Amgen (AMGN) Stock Forecast & Price Target

6,860 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

11 Buy

11 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$365.76

▲(2.94% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $365.76 with a high forecast of $432.00 and a low forecast of $295.00. The average price target represents a 2.94% change from the last price of $355.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"274":"$274","433":"$433","313.75":"$313.8","353.5":"$353.5","393.25":"$393.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$432.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":365.76190476190476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$365.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$295.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[274,313.75,353.5,393.25,433],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,353.28,359.3353846153846,365.3907692307692,371.44615384615383,377.5015384615384,383.55692307692306,389.6123076923077,395.6676923076923,401.7230769230769,407.77846153846156,413.83384615384614,419.8892307692308,425.94461538461536,{"y":432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,353.28,354.2401465201465,355.200293040293,356.16043956043956,357.12058608058607,358.0807326007326,359.0408791208791,360.00102564102565,360.96117216117216,361.92131868131867,362.8814652014652,363.84161172161174,364.80175824175825,{"y":365.76190476190476,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,353.28,348.79692307692306,344.31384615384616,339.8307692307692,335.3476923076923,330.8646153846154,326.38153846153847,321.8984615384615,317.4153846153846,312.9323076923077,308.4492307692308,303.9661538461538,299.4830769230769,{"y":295,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":297.584,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.147,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":282.167,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.393,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283.706,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.346,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.277,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.167,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.057,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.308,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":385.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":353.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$432.00

Average Price Target$365.76

Lowest Price Target$295.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

$432

Buy

21.59%

Upside

Reiterated

04/24/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Medpace Holdings (NASDAQ: MEDP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

$366

Hold

3.01%

Upside

Initiated

04/21/26

Amgen (AMGN) Initiated with a Hold at Canaccord Genuity

Courtney Breen

Bernstein

$335

Hold

-5.71%

Downside

Reiterated

04/21/26

Amgen (AMGN) Receives a Hold from Bernstein

Emily Field

Barclays

$350

Hold

-1.49%

Downside

Reiterated

04/21/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Brookdale Senior Living (NYSE: BKD) and 10x Genomics (NASDAQ: TXG)

Tazeen Ahmad

Bank of America Securities

$304

Sell

-14.44%

Downside

Reiterated

04/15/26

Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

Michael Yee

UBS

$390→$400

Buy

12.58%

Upside

Reiterated

04/13/26

Amgen price target raised to $400 from $390 at UBSAmgen price target raised to $400 from $390 at UBS

Terence Flynn

Morgan Stanley

$309→$326

Hold

-8.25%

Downside

Assigned

04/10/26

Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

Gregory Renza

Truist Financial

$319→$325

Hold

-8.53%

Downside

Reiterated

04/08/26

Amgen price target raised to $325 from $319 at TruistAmgen price target raised to $325 from $319 at Truist

Vamil Divan

Guggenheim

$347→$351

Hold

-1.21%

Downside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), ProQR (NASDAQ: PRQR) and Spyre Therapeutics (NASDAQ: SYRE)

Carter Gould

Cantor Fitzgerald

$350

Hold

-1.49%

Downside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

Geoff Meacham

Citi

$345

Hold

-2.90%

Downside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Boston Scientific (NYSE: BSX)

Luca Issi

RBC Capital

$360→$370

Buy

4.14%

Upside

Reiterated

04/07/26

Amgen price target raised to $370 from $360 at RBC CapitalAmgen price target raised to $370 from $360 at RBC Capital

Yaron Werber

TD Cowen

$420

Buy

18.21%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Mohit Bansal

Wells Fargo

$390

Hold

9.77%

Upside

Assigned

04/02/26

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

$432

Buy

21.59%

Upside

Reiterated

04/24/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Medpace Holdings (NASDAQ: MEDP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

$366

Hold

3.01%

Upside

Initiated

04/21/26

Amgen (AMGN) Initiated with a Hold at Canaccord Genuity

Courtney Breen

Bernstein

$335

Hold

-5.71%

Downside

Reiterated

04/21/26

Amgen (AMGN) Receives a Hold from Bernstein

Emily Field

Barclays

$350

Hold

-1.49%

Downside

Reiterated

04/21/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Brookdale Senior Living (NYSE: BKD) and 10x Genomics (NASDAQ: TXG)

Tazeen Ahmad

Bank of America Securities

$304

Sell

-14.44%

Downside

Reiterated

04/15/26

Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

Michael Yee

UBS

$390→$400

Buy

12.58%

Upside

Reiterated

04/13/26

Amgen price target raised to $400 from $390 at UBSAmgen price target raised to $400 from $390 at UBS

Terence Flynn

Morgan Stanley

$309→$326

Hold

-8.25%

Downside

Assigned

04/10/26

Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

Gregory Renza

Truist Financial

$319→$325

Hold

-8.53%

Downside

Reiterated

04/08/26

Amgen price target raised to $325 from $319 at TruistAmgen price target raised to $325 from $319 at Truist

Vamil Divan

Guggenheim

$347→$351

Hold

-1.21%

Downside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), ProQR (NASDAQ: PRQR) and Spyre Therapeutics (NASDAQ: SYRE)

Carter Gould

Cantor Fitzgerald

$350

Hold

-1.49%

Downside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

Geoff Meacham

Citi

$345

Hold

-2.90%

Downside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Boston Scientific (NYSE: BSX)

Luca Issi

RBC Capital

$360→$370

Buy

4.14%

Upside

Reiterated

04/07/26

Amgen price target raised to $370 from $360 at RBC CapitalAmgen price target raised to $370 from $360 at RBC Capital

Yaron Werber

TD Cowen

$420

Buy

18.21%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Mohit Bansal

Wells Fargo

$390

Hold

9.77%

Upside

Assigned

04/02/26

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

xxx

Success Rate

29/43 ratings generated profit

Average Return

+4.86%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.44% of your transactions generating a profit, with an average return of +4.86% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

13/16 ratings generated profit

Average Return

+16.10%

Copying David Amsellem's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +16.10% per trade.

2 Years

xxx

Success Rate

30/31 ratings generated profit

Average Return

+20.00%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.77% of your transactions generating a profit, with an average return of +20.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 21 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. AMGN average Analyst price target in the past 3 months is 365.76.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $4.77 with a range of $4.17 to $5.24. The previous quarter’s EPS was $5.29. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.58B with a range of $8.34B to $9.18B. The previous quarter’s sales results were $9.90B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 365.76.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen has 2.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 365.76. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $432.00 ,the lowest forecast is $295.00. The average price target represents 2.94% Increase from the current price of $355.3.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Detailed List of Analyst Forecasts